Immune system effector function enhancement

Immune system effector function enhancement refers to strategies and mechanisms by which the activity of immune system effector cells (such as natural killer cells, macrophages, neutrophils, and dendritic cells) or effector molecules (especially antibodies) is increased, often in the context of infections, cancer, or autoimmunity. Central to these mechanisms are antibody Fc-mediated functions (including ADCC, ADCP, CDC) that bridge innate and adaptive immunity. Effector functions can be increased through antibody engineering (e.g., modifying Fc affinity for receptors), modulating antigen recognition, or altering immune cell activation states. While enhancing effector functions can improve pathogen clearance and anti-tumor efficacy, it also carries risks, such as increased inflammation, ADE, and immune-mediated tissue damage. This concept, though not a molecular target itself, shapes the design and evaluation of many immunotherapies, especially monoclonal antibodies and certain vaccines.

Other names

Effector function enhancementEnhanced immune effector functionImmune effector potentiation

Enhancement of antibody-dependent cellular cytotoxicity (ADCC); Antibody-dependent cellular phagocytosis (ADCP); Complement-dependent cytotoxicity (CDC); Modulation of Fc receptor interactions; Modulation of immune cell activation/maturation.